The DOI matches its Crossref record; 176 of the 176 references it cites were found in a registry or an index.
Management of Graves’ Ophthalmopathy: Reality and Perspectives*
Open accessAbstract
Graves’ ophthalmopathy is an debilitating disease impairing the quality of life of affected individuals. Despite recent progress in the understanding of its pathogenesis, treatment is often not satisfactory. In mild cases, local therapeutic measures (artificial tears and ointments, sunglasses, nocturnal taping of the eyes, prisms) can control symptoms and signs. In severe forms of the disease (3–5%), aggressive measures are required. If the disease is active, high-dose glucocorticoids and/or orbital radiotherapy, or orbital decompression represent the mainstay of treatment. If the disease is severe but inactive, orbital decompression is preferred. Novel treatments such as somatostatin analogs or intravenous immunoglobulins are under evaluation. Rehabilitative (extraocular muscle or eyelid) surgery is often needed after treatment and inactivation of eye disease. Correction of both hyper- and hypothyroidism is crucial for the ophthalmopathy. Antithyroid drugs and thyroidectomy do not influence the course of the ophthalmopathy, whereas radioiodine treatment may cause the progression of preexisting ophthalmopathy, especially in smokers. The exacerbation, however, is prevented by glucocorticoids. In addition, thyroid ablation may prove beneficial for the ophthalmopathy in view of the pathogenetic model relating eye disease to autoimmune reactions directed against antigens shared by the thyroid and the orbit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Oei, H. Y., van Hagen, M., Postema, P. T. E., de Jong, M., Reubi, J. C., et al. (1993) · European Journal of Nuclear Medicine · doi:10.1007/bf00181765 · Cited by 1,564
Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy
Mourits, M. P., Prummel, M. F., Wiersinga, W. M., & Koornneef, L. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.2331047.x · Cited by 1,001
Solomon, S. (1969) · The Lancet · doi:10.1016/s0140-6736(69)92136-9 · Cited by 844
Mourits, M. P., Koornneef, L., Wiersinga, W. M., Prummel, M. F., Berghout, A., & van der Gaag, R. (1989) · British Journal of Ophthalmology · doi:10.1136/bjo.73.8.639 · Cited by 721
Relation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy
Bartalena, L., Marcocci, C., Bogazzi, F., Manetti, L., Tanda, M. L., Dell'Unto, E., Bruno-Bossio, G., Nardi, M., Bartolomei, M. P., Lepri, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380201 · Cited by 715
Self-citationPathogenesis of Graves' Ophthalmopathy
Epstein, F. H., Bahn, R. S., & Heufelder, A. E. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292007 · Cited by 605
Graves' Ophthalmopathy: Current Concepts Regarding Pathogenesis and Management*
BURCH, H. B., & WARTOFSKY, L. (1993) · Endocrine Reviews · doi:10.1210/edrv-14-6-747 · Cited by 598
Occurrence of Ophthalmopathy after Treatment for Graves' Hyperthyroidism
Tallstedt, L., Lundell, G., Tørring, O., Wallin, G., Ljunggren, J.-G., Blomgren, H., & Taube, A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206253262603 · Cited by 521
Smoking and Risk of Graves' Disease
Prummel, M. F. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500040045034 · Cited by 503
Cited by
Bahn, R. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0905750 · Cited by 1,552
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO
Bartalena, L., Baldeschi, L., Dickinson, A., Eckstein, A., Kendall-Taylor, P., Marcocci, C., Mourits, M., Perros, P., Boboridis, K., Boschi, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0666 · Cited by 795
Self-citationSelenium and the Course of Mild Graves' Orbitopathy
Marcocci, C., Kahaly, G. J., Krassas, G. E., Bartalena, L., Prummel, M., Stahl, M., Altea, M. A., Nardi, M., Pitz, S., Boboridis, K., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012985 · Cited by 619
Self-citationEpidemiology and Prevention of Graves' Ophthalmopathy
Wiersinga, W. M., & Bartalena, L. (2002) · Thyroid · doi:10.1089/105072502761016476 · Cited by 458
Self-citationRandomized, Single Blind Trial of Intravenous versus Oral Steroid Monotherapy in Graves’ Orbitopathy
Kahaly, G. J., Pitz, S., Hommel, G., & Dittmar, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0148 · Cited by 423
Bartalena, L., Baldeschi, L., Dickinson, A. J., Eckstein, A., Kendall-Taylor, P., Marcocci, C., Mourits, M. P., Perros, P., Boboridis, K., Boschi, A., et al. (2008) · Thyroid · doi:10.1089/thy.2007.0315 · Cited by 406
Self-citationBartalena, L., Krassas, G. E., Wiersinga, W., Marcocci, C., Salvi, M., Daumerie, C., Bournaud, C., Stahl, M., Sassi, L., Veronesi, G., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2389 · Cited by 370
Self-citationEpidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy
Bartalena, L., Piantanida, E., Gallo, D., Lai, A., & Tanda, M. L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.615993 · Cited by 369
Self-citationThyroid hormones states and brain development interactions
Ahmed, O. M., El‐Gareib, A. W., El‐bakry, A. M., Abd El‐Tawab, S. M., & Ahmed, R. G. (2008) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2007.09.011 · Cited by 341
Bartalena, L., & Tanda, M. L. (2009) · New England Journal of Medicine · doi:10.1056/nejmcp0806317 · Cited by 336
Self-citationTanda, M. L., Piantanida, E., Liparulo, L., Veronesi, G., Lai, A., Sassi, L., Pariani, N., Gallo, D., Azzolini, C., Ferrario, M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3873 · Cited by 328
Self-citationNew insights into the pathogenesis and nonsurgical management of Graves orbitopathy
Taylor, P. N., Zhang, L., Lee, R. W. J., Muller, I., Ezra, D. G., Dayan, C. M., Kahaly, G. J., & Ludgate, M. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0305-4 · Cited by 315
A review of the current use of rituximab in autoimmune diseases
Gürcan, H. M., Keskin, D. B., Stern, J. N. H., Nitzberg, M. A., Shekhani, H., & Ahmed, A. R. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2008.10.004 · Cited by 314
Marcocci, C. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.8.3562 · Cited by 309
Self-citation_, _., Wiersinga, W. M., Perros, P., Kahaly, G. J., Mourits, M. P., Baldeschi, L., Boboridis, K., Boschi, A., Dickinson, A. J., Kendall-Taylor, P., et al. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02230 · Cited by 302
Self-citationThe environment and autoimmune thyroid diseases
Prummel, M., Strieder, T., & Wiersinga, W. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500605 · Cited by 302
Diagnosis and management of Graves disease: a global overview
Bartalena, L. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.193 · Cited by 296
Self-citationExtrathyroidal manifestations of Graves’ disease: a 2014 update
Bartalena, L., & Fatourechi, V. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0097-2 · Cited by 279
Self-citationDiagnosis and classification of Graves' disease
Menconi, F., Marcocci, C., & Marinò, M. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.013 · Cited by 276
Self-citationPerros, P., Kendall-Taylor, P., Neoh, C., Frewin, S., & Dickinson, J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0507 · Cited by 156
Lai, A., Sassi, L., Compri, E., Marino, F., Sivelli, P., Piantanida, E., Tanda, M. L., & Bartalena, L. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2130 · Cited by 129
Self-citationThe Dilemma of How to Manage Graves' Hyperthyroidism in Patients with Associated Orbitopathy
Bartalena, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2329 · Cited by 93
Self-citationKahaly, G. J., Bartalena, L., & Hegedüs, L. (2011) · Thyroid® · doi:10.1089/thy.2011.2106.ed3 · Cited by 80
Self-citationMuller, I., Moran, C., Lecumberri, B., Decallonne, B., Robertson, N., Jones, J., & Dayan, C. M. (2019) · European Thyroid Journal · doi:10.1159/000500881 · Cited by 78
De Bellis, A., Conzo, G., Cennamo, G., Pane, E., Bellastella, G., Colella, C., Iacovo, A. D., Paglionico, V. A., Sinisi, A. A., Wall, J. R., et al. (2012) · Endocrine · doi:10.1007/s12020-011-9559-x · Cited by 69
The Natural History of Subclinical Hyperthyroidism in Graves’ Disease: The Rule of Thirds
Zhyzhneuskaya, S., Addison, C., Tsatlidis, V., Weaver, J. U., & Razvi, S. (2016) · Thyroid · doi:10.1089/thy.2015.0470 · Cited by 22
Metadata
- Authors
- Bartalena, L., Pinchera, A., & Marcocci, C.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2000-04-01
- Volume
- 21
- Issue
- 2
- Pages
- 168-199
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2133188970
- Cited by
- 677
- References
- 176
- FWCI
- 16.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.